Treatment of Temporomandibular Joint Osteoarthritis by Viscosupplement. Satisfaction Predictive Factors (ARTEMIS)
|ClinicalTrials.gov Identifier: NCT03627429|
Recruitment Status : Completed
First Posted : August 13, 2018
Last Update Posted : August 13, 2018
The arthritis of temporomandibular joint is the most frequent degenerative disease of the jaw joint. Several clinical studies recommend the recourse to the viscosupplement because of its efficiency in the long term.
The present research has for objective to find clinical factors predictive of success or failure of viscosupplementation in ATM such as clinical severity before injection, the presence of a limited mouth opening or lenght of symptoms.
It is an open observational monocentrical prospective study. The recruitment is competitive and the study will be ended when 44 patients will have been included by taking into account a risk of trial exits or of lost of sight of 10 %.The main criterion is the influence of the radiological stage on the answer to the treatment.
Duration of inclusion 6 months. Duration of follow-up 6 months. Total duration of the study 12 months.
|Condition or disease|
|Arthritis of Temporomandibular Joint Temporomandibular Arthritis|
Forty patients presenting an ATM asserted by radiography and justifying a viscosupplement, without other selection criterion than the opinion of the investigator concerning the legitimacy of a viscosupplement and the agreement of the patient participating in the study.
The data collected during the consultations at J0, J90 and J180 will be inputed by the investigator in the paper version of the CRF.
The informations collected during the initial consultation (J0) are: demographic (sex, age, weight, size), pathological (history of the disease, target side, previous treatments, evaluation of pain at chewing and palpation (scale of Likert : 11 points), the inter-incisive distance during the maximal opening.
The informations collected during J90 and the final consultation (J180) are: the evaluation of pain at chewing and palpation (scale of Likert 11 points), the perception by the patient of the efficiency of the treatment (scale of Likert 4 points), patient satisfaction score, variation of its consumption of analgesic or of AINS (scale of Likert 5 points).
A descriptive analysis will be performed to characterize the demographic data, the history of the disease and its treatments, as well as the clinical and radiological data of the patients in the date of the inclusion.
The response to the treatment (Yes/No) will be estimated by 3 complementary terms, and for each one of them, the predictive response factors will be studied. Each patient will be classified in one of the treatment response categories based on the patients efficacy assessment, the pain decrease of at least 3 points or of at least 50% on the Likert scale, the satisfaction level of the patient.
The coefficients of the multivariate models (ANCOVA and mixed model) will be considered as significant if their p-value is inferior to the threshold of 5%.
|Study Type :||Observational|
|Actual Enrollment :||36 participants|
|Official Title:||Treatment of Temporomandibular Joint Osteoarthritis by an Intra-articular Injection of Hyaluronic Acid. Study of Patient Satisfaction Predictive Factors, 6 Months After a Single Injection of Hyaluronic Acid.|
|Study Start Date :||April 30, 2016|
|Actual Primary Completion Date :||April 2018|
|Actual Study Completion Date :||June 2018|
- clinical factors associated with the treatment response in temporomandibular joint arthritis [ Time Frame: 6 months ]Assessment of since how long the patient has these pains (in months)
- clinical factors associated with the treatment response in temporomandibular joint arthritis [ Time Frame: 6 months ]Assessment of the pain intensity on a 11-point Likert scale
- clinical factors associated with the treatment response in temporomandibular joint arthritis [ Time Frame: 6 months ]Assessment of the mouth opening (in mm)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03627429
|Principal Investigator:||DOMINIQUE BARON, MD||CH LANNION|